Key Points
- Omeros CAO David Borges sold 5,000 shares at an average price of $16.95, generating $84,750 and reducing his position by 50%. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Omeros reported quarterly EPS of $0.02, beating the consensus estimate of a $0.27 loss, while revenue of $28.53 million exceeded estimates of $12.69 million.
- The stock opened at $17.36, near its 52-week high of $18.14. Analysts maintain a “Moderate Buy” consensus with an average price target of $38.00, while institutional investors own 48.79% of the company.
Omeros Corporation (NASDAQ:OMER - Get Free Report) CAO David Borges sold 5,000 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $16.95, for a total value of $84,750.00. Following the completion of the transaction, the chief accounting officer owned 5,000 shares of the company's stock, valued at $84,750. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Omeros Price Performance
Omeros stock opened at $17.36 on Tuesday. The firm's 50 day simple moving average is $11.04 and its 200-day simple moving average is $11.58. Omeros Corporation has a fifty-two week low of $3.94 and a fifty-two week high of $18.14. The company has a market cap of $1.26 billion, a P/E ratio of 13.56 and a beta of 2.54.
Omeros (NASDAQ:OMER - Get Free Report) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.29. The firm had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. On average, analysts expect that Omeros Corporation will post -0.37 EPS for the current fiscal year.
Hedge Funds Weigh In On Omeros
A number of institutional investors have recently modified their holdings of the company. State of Wyoming bought a new stake in shares of Omeros during the 4th quarter worth $25,000. B. Riley Wealth Advisors Inc. acquired a new position in Omeros during the 2nd quarter worth $32,000. Caitong International Asset Management Co. Ltd bought a new stake in Omeros during the fourth quarter valued at about $33,000. Assetmark Inc. acquired a new stake in shares of Omeros in the first quarter valued at about $38,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Omeros by 829.6% in the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company's stock worth $40,000 after purchasing an additional 11,971 shares during the period. Institutional investors own 48.79% of the company's stock.
Analyst Upgrades and Downgrades
OMER has been the topic of a number of recent research reports. Wall Street Zen upgraded Omeros from a "hold" rating to a "buy" rating in a research note on Saturday. Weiss Ratings upgraded Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, August 5th. HC Wainwright reissued a "buy" rating on shares of Omeros in a research note on Monday, July 27th. Zacks Research downgraded Omeros from a "strong-buy" rating to a "hold" rating in a report on Monday, July 13th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $36.00 price objective on shares of Omeros in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Omeros currently has an average rating of "Moderate Buy" and a consensus target price of $38.00.
Check Out Our Latest Research Report on Omeros
About Omeros
(
Get Free Report)
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
